DEF: Voyager Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals

Voyager Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on June 3, 2025, featuring proposals including director elections, executive compensation, auditor ratification, and stock incentive plan approvals.

Summary

• Voyager Therapeutics will hold its 2025 Annual Meeting of Stockholders on June 3, 2025, at 11:00 a.m. Eastern Time, at its Lexington, Massachusetts offices.
• Stockholders of record as of April 7, 2025, are entitled to vote.
• The meeting will address the election of four Class I directors, an advisory vote on executive compensation, ratification of Ernst & Young LLP as the independent auditor, and approval of the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan.
• The Board of Directors recommends voting in favor of all proposals.
• The company is taking advantage of SEC rules to furnish proxy materials over the internet, reducing environmental impact and costs.
• As of April 7, 2025, there were 55,313,413 shares of common stock outstanding.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for stockholders. It expresses confidence in the company's future and the importance of the proposals for its success.

Positives

• The company is reducing environmental impact and costs by providing proxy materials online.
• Stockholders have the opportunity to express their views on executive compensation.
• The proposed 2025 Stock Incentive Plan aims to attract, retain, and motivate key personnel.
• The Amended and Restated 2015 Employee Stock Purchase Plan seeks to encourage stock ownership by employees.

Future Outlook

The company intends to register the additional shares reserved for issuance under the 2025 Plan by filing a Registration Statement on Form S-8 as soon as practicable following stockholder approval. The company expects that the proposed share pool under the 2025 Plan will allow it to continue to grant equity awards at its historic rates for approximately two years.

Management Comments

• Alfred Sandrock, M.D., Ph.D., Chief Executive Officer, President and Director, stated that it is important that shares be represented at the Annual Meeting.

Industry Context

The document reflects standard corporate governance practices for publicly traded biopharmaceutical companies, including seeking stockholder approval for key decisions such as executive compensation and equity incentive plans.

Comparison to Industry Standards

• The proxy statement includes standard sections and disclosures expected for a US publicly traded company, such as executive and director compensation, related party transactions, and corporate governance practices.
• The peer group used for compensation benchmarking includes companies like 4D Molecular Therapeutics, Editas Medicine, and Tenaya Therapeutics, which are common comparables for a gene therapy company of Voyager's size and stage.
• The discussion of overhang and burn rate is consistent with how institutional investors evaluate equity compensation plans.
• The inclusion of a compensation recovery (clawback) policy aligns with current regulatory requirements and best practices in corporate governance.
• The detailed description of the proposed 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan is typical for seeking stockholder approval of such plans.

Stakeholder Impact

• Shareholders are asked to vote on matters that directly affect the company's governance and compensation practices.
• Employees may benefit from the approval of the stock incentive plan and employee stock purchase plan.
• The outcome of the proposals can influence the company's ability to attract and retain talent, impacting its long-term performance.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 3, 2025, and announce the results.
• The company will implement the approved proposals, including the new stock incentive plan and employee stock purchase plan.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Stock Incentive Plan, Employee Stock Purchase Plan, Director Election, Ernst & Young, Auditor Ratification, Corporate Governance